We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0JYL market cap is 261.96M. The company's latest EPS is USD -2.5911 and P/E is -0.21.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 1.72M | 15.35M | 25.48M | 30.99M |
| Operating Income | -54.42M | -67.94M | -96.93M | -112.79M | -131.49M |
| Net Income | -54.12M | -67.48M | -98.78M | -19.82M | -141.41M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 98.84M | 150.46M | 136.84M | 259.52M | 170.91M |
| Total Liabilities | 11.07M | 13.26M | 83.35M | 143.52M | 154.14M |
| Total Equity | 59.57M | 137.2M | 53.49M | 116M | 16.77M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -48.63M | -60.91M | -55.48M | -112.89M | -118M |
| Investing | 3.88M | -738k | -1.42M | 105.77M | -28.61M |
| Financing | 67.97M | 109.22M | 41.31M | 124.74M | 26.63M |
| Market Cap | 261.96M |
| Price to Earnings Ratio | -0.21 |
| Price to Sales Ratio | 0.95 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 1.76 |
| Dividend Yield | - |
| Shares Outstanding | 54.57M |
| Average Volume (1 week) | 51.34k |
| Average Volume (1 Month) | 17.69k |
| 52 Week Change | 0.00% |
| 52 Week High | 4.80 |
| 52 Week Low | 4.80 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Marinus Pharmaceuticals Inc |
| Address |
3411 silverside road tatnall building wilmington, delaware 19810 |
| Website | https://www.marinuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
